Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Moderna, Inc. stock logo
MRNA
Moderna
$26.69
-0.7%
$29.19
$23.15
$91.99
$10.46B1.838.58 million shs5.79 million shs
QIAGEN N.V. stock logo
QGEN
QIAGEN
$48.95
-0.6%
$48.29
$37.63
$51.88
$10.94B0.641.57 million shs841,447 shs
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$14.13
-0.9%
$14.78
$12.26
$16.85
$11.91B0.291.48 million shs1.75 million shs
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
$32.29
+1.0%
$35.79
$6.76
$46.98
$3.07B0.481.61 million shs963,811 shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Moderna, Inc. stock logo
MRNA
Moderna
+4.79%+0.67%-18.19%+13.70%-67.56%
QIAGEN N.V. stock logo
QGEN
QIAGEN
+0.55%+3.75%+2.07%+16.73%+10.29%
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
+2.55%+6.78%-2.16%-0.90%-14.43%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
-0.68%-7.63%-17.13%+3.73%+229.35%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Moderna, Inc. stock logo
MRNA
Moderna
4.4568 of 5 stars
4.02.00.04.62.42.50.6
QIAGEN N.V. stock logo
QGEN
QIAGEN
3.8769 of 5 stars
1.12.01.74.52.71.72.5
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
3.0878 of 5 stars
2.54.01.70.03.20.01.9
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
4.4791 of 5 stars
4.60.00.04.42.23.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Moderna, Inc. stock logo
MRNA
Moderna
2.04
Hold$43.5963.31% Upside
QIAGEN N.V. stock logo
QGEN
QIAGEN
2.27
Hold$49.691.50% Upside
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
3.00
Buy$16.9520.00% Upside
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
3.22
Buy$45.1439.80% Upside

Current Analyst Ratings Breakdown

Latest SRRK, MRNA, RDY, and QGEN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/7/2025
QIAGEN N.V. stock logo
QGEN
QIAGEN
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
8/7/2025
QIAGEN N.V. stock logo
QGEN
QIAGEN
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$48.00 ➝ $50.00
8/7/2025
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$57.00 ➝ $45.00
8/4/2025
Moderna, Inc. stock logo
MRNA
Moderna
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$40.00 ➝ $31.00
8/1/2025
Moderna, Inc. stock logo
MRNA
Moderna
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$32.00
8/1/2025
Moderna, Inc. stock logo
MRNA
Moderna
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$26.00
8/1/2025
Moderna, Inc. stock logo
MRNA
Moderna
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$40.00
8/1/2025
Moderna, Inc. stock logo
MRNA
Moderna
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingEqual Weight ➝ Equal Weight$32.00
7/30/2025
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetStrong-Buy$53.00
7/22/2025
Moderna, Inc. stock logo
MRNA
Moderna
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderperform ➝ Underperform$26.00 ➝ $25.00
7/17/2025
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight
(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Moderna, Inc. stock logo
MRNA
Moderna
$3.24B3.21N/AN/A$24.16 per share1.10
QIAGEN N.V. stock logo
QGEN
QIAGEN
$1.98B5.50$3.19 per share15.36$15.77 per share3.10
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$3.81B3.09$1.02 per share13.81$4.94 per share2.86
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
$33.19M93.52N/AN/A$2.43 per share13.29
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Moderna, Inc. stock logo
MRNA
Moderna
-$3.56B-$7.53N/AN/AN/A-94.31%-25.96%-20.09%N/A
QIAGEN N.V. stock logo
QGEN
QIAGEN
$83.59M$1.6928.9219.902.5818.30%14.77%8.87%N/A
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$663M$0.6621.4017.235.7416.99%17.25%11.63%N/A
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
-$246.29M-$2.91N/AN/AN/AN/A-127.11%-90.09%N/A

Latest SRRK, MRNA, RDY, and QGEN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
-$0.66-$0.98-$0.32-$0.98$0.11 millionN/A
8/5/2025Q2 2025
QIAGEN N.V. stock logo
QGEN
QIAGEN
$0.60$0.60N/A$0.44$523.97 million$533.54 million
8/1/2025Q2 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.99-$2.13+$0.86-$2.13$116.26 million$142.00 million
7/23/2025Q1 25/26
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$0.18$0.20+$0.02$0.20$88.27 billion$988.82 million
5/14/2025Q1 2025
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
-$0.63-$0.67-$0.04-$0.67N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
QIAGEN N.V. stock logo
QGEN
QIAGEN
$0.250.51%N/A14.79%N/A
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$0.070.50%N/A10.61%N/A
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
N/AN/AN/AN/AN/A

Latest SRRK, MRNA, RDY, and QGEN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/1/2025
QIAGEN N.V. stock logo
QGEN
QIAGEN
$0.250.52%7/2/20257/3/20257/10/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Moderna, Inc. stock logo
MRNA
Moderna
N/A
3.93
3.77
QIAGEN N.V. stock logo
QGEN
QIAGEN
0.25
1.61
1.35
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
0.01
1.89
1.36
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
0.21
6.33
6.33

Institutional Ownership

CompanyInstitutional Ownership
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
QIAGEN N.V. stock logo
QGEN
QIAGEN
70.00%
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
3.85%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
91.08%

Insider Ownership

CompanyInsider Ownership
Moderna, Inc. stock logo
MRNA
Moderna
11.00%
QIAGEN N.V. stock logo
QGEN
QIAGEN
9.00%
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
2.00%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
13.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Moderna, Inc. stock logo
MRNA
Moderna
5,800389.08 million346.28 millionOptionable
QIAGEN N.V. stock logo
QGEN
QIAGEN
5,765222.29 million202.29 millionOptionable
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
27,811834.90 million818.20 millionOptionable
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
14096.13 million83.34 millionOptionable

Recent News About These Companies

Scholar Rock Holding: Upcoming Milestone Approaches
Cantor Fitzgerald Lowers Earnings Estimates for Scholar Rock
Wedbush Issues Negative Forecast for Scholar Rock Earnings
Analysts Offer Predictions for Scholar Rock FY2025 Earnings
Wedbush Brokers Lower Earnings Estimates for Scholar Rock
Scholar Rock (SRRK) Q2 Loss Widens 63%
Why Scholar Rock Stock Wilted on Wednesday

New MarketBeat Followers Over Time

Media Sentiment Over Time

Moderna stock logo

Moderna NASDAQ:MRNA

$26.69 -0.20 (-0.74%)
Closing price 04:00 PM Eastern
Extended Trading
$26.74 +0.04 (+0.17%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

QIAGEN stock logo

QIAGEN NYSE:QGEN

$48.95 -0.28 (-0.56%)
Closing price 03:59 PM Eastern
Extended Trading
$48.95 0.00 (-0.01%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

Dr. Reddy's Laboratories stock logo

Dr. Reddy's Laboratories NYSE:RDY

$14.12 -0.14 (-0.95%)
Closing price 03:59 PM Eastern
Extended Trading
$14.12 0.00 (0.00%)
As of 04:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Scholar Rock stock logo

Scholar Rock NASDAQ:SRRK

$32.29 +0.31 (+0.97%)
Closing price 04:00 PM Eastern
Extended Trading
$32.30 +0.01 (+0.02%)
As of 07:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.